Daiichi-Sankyo co., ltd, manufacturer of pharmaceuticals, has reported that profit attributable to owners of the company for the first quarter ended June 30, 2014 was JPY19.99 billion, or JPY28.34 per diluted share, compared to JPY15.02 billion, or ... Individual.com, 7 hours ago
Daiichi Sankyo initiates testing of etanercept biosimilar in Japan20-08-2014 - Pharma Letter, 4 hours ago
Daiichi Sankyo Begins Etanercept Biosimilar Trial - PharmaAsia, 7 hours ago
NEW DELHI: , which is in the process of acquiring control of Ranbaxy Laboratories from Daiichi Sankyo, will soon put its purchase to work through the exclusive marketing opportunity offered by two drugs in the US, rationalising research and other ...Economic Times, 1 week ago Sun Pharma banks on Daiichi Sankyo to enter Japan market: Reports India Infoline, 1 week ago
Sun Pharmaceuticals is reportedly planning to enter the Japanese market riding on its association with Daiichi Sankyo from which it is buying Ranbaxy Laboratories. The Economic Times has reported that the drug company is likely to introduce its ...Pharmaceutical Business Review, 1 week ago Bharat Book Bureau: Global Pharmaceutical and Biotechnology Outlook 2014 - Japan Pharma Pharmacy Choice, 6 days ago SUN PLANS TO RISE IN JAPAN'S PHARMA MARKET Pharmacy Choice, 1 week ago
BOSTON, MA — Authors of a new meta-analysis comparing a bivalirudin (Angiomax, the Medicines Company)-based regimen vs a heparin-based approach in patients undergoing PCI say they hope their paper helps the medical community to understand the ...Diabetes Care, 5 days ago
Biota Pharmaceuticals, a biopharmaceutical company focused on the discovery and development of products to prevent and treat serious and potentially life-threatening viral respiratory infectious diseases, announced top-line data from a randomised, ...PharmaBiz, 2 weeks ago Biota Reports Top-Line Data From Its Phase 2 "IGLOO" Trial of Laninamivir Octanoate Stock Nod, 2 weeks ago News Scan for Aug 01, 2014 Centre For Infectious Disease Research and Policy, 2 weeks ago Biota Pharma Reports Top-line Data From Laninamivir Octanoate Phase 2 Trial RTTNews.com, 2 weeks ago
Sun Pharma's April-June net profit was 13.91 billion rupees ($227.73 million), compared with a net loss of 12.76 billion rupees a year earlier. (Reuters) Summary Sun Pharma's April-June net profit was 13.91 billion rupees ($227.73 million), ...Financial Express, 1 week ago Sun, Ranbaxy hire Mckinsey for merger assistance Rediff.com, 1 month ago Too Big To Ignore Businessworld India, 7 hours ago Sun Pharma registers Rs 1391 crores profit in Q1 Bio Spectrum Asia, 2 days ago
Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2014-2024: Opportunities for Leading Companies
Alzheimer's medicine - your guide to technologies, trends and revenues Where is the Alzheimer's disease treatment market heading? Visiongain's new report gives you revenue predictions for those drugs and diagnostic tests from 2014, helping ...Global Information Inc, 2 days ago
More from: , ADVFN India...and 1 other sources
SOUTH SAN FRANCISCO, Calif. The Company is focusing its resources on advanced clinical studies of fostamatinib in two indications. The fostamatinib programs include a recently initiated Phase 3 study in patients with immune thrombocytopenic ...Industrial Info Financials, 1 week ago An antidote for Factor Xa inhibitors Drug Discovery News, 1 week ago Rigel Announces Second Quarter 2014 Financial Results Review Seeker, 2 weeks ago ArQule Reports Second Quarter 2014 Financial Results Morningstar.com, 2 weeks ago
Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, ...BizWire Express, 5 hours ago 48% of US Physicians Ready for iPhone 6 "Phablet" and 37% Ready for the iWatch Stock Nod, 2 weeks ago
FirstWord Lists: Which companies in the oncology space have the most effective medical affairs teams?
The importance of a sound medical affairs team to the commercial success of a marketed drug cannot be understated, particularly in oncology setting where treatment paradigms are shifting rapidly based on a constant flow of clinical data and ...FirstWord Pharma, 1 week ago
on your WebpageAdd Widget >Get your members hooked!